RECOMMENDATIONS WHEN SEARCHING:
‘ESSENTIAL OILS’ <=> ‘ESSENTIAL OIL’
‘BREAD WITH SEEDS’ <=> ‘BREAD SEEDS’
'ESSENTIAL OIL' <=> 'PRANAROM ESSENTIAL OIL'
* The result also can include products / manufacturers that have words that are similar to the one you are looking for, even if they do not match exactly.
The development of Lyprinol was in 1973 when the MacLab group became interested in growing mussels and tun extract from New Zealand green lipped mussel as a natural treatment for arthritis.In 1975 the MacLab group formed a joint venture to market a mussel extract of freeze-dried green mussel.
The Pharmalink company has accumulated more than three decades of experience and research on New Zealand Perna Canaliculus, culminating in the development of Lyprinol®. This innovative breakthrough was led by the MacLab group, who not only invested in the company, but were also its partners.
The beginning of the development of Lyprinol® dates back to 1973, when the MacLab group became interested in mussel farming operations and proposed the idea of creating a New Zealand green lip mussel extract as a natural treatment for arthritis.
In 1975, they established a joint venture to market a powdered freeze-dried Perna Caniculus mussel extract, under the name "Seatone". This product was successful in Australia, New Zealand and later in the United Kingdom, despite opposition from some medical sectors.
Despite inconclusive early clinical studies, in 1980 Drs Sheila and Robert Gibson conducted a larger study that demonstrated the value of mussel extract in treating certain forms of arthritis, generating renewed interest in the product.
In 1982, the MacLab group acquired a mussel powder production factory in New Zealand and began a collaboration with the Royal Melbourne University Institute of Technology to research the properties of mussels.
In 1983, during a visit to Japan, a member of the MacLab group met Professor Takuo Kosuge, who offered the collaboration of his research group to study the mussel. Despite technical challenges, the mussel powder was eventually stabilized, allowing for more rigorous clinical research.
In 1997, a comparative study highlighted the difference between stabilized and unstable mussel powder in terms of beneficial activity. This led to the development of new extraction methods, such as the company's patented supercritical fluid extraction (SFE) process.
In 1992, Dr. Henry Betts joined the project and performed in vitro analyzes that confirmed the activity of certain fractions of the mussel. These results led to in vivo studies with laboratory animals, which corroborated the effectiveness of the product.
As a result of years of research, several international patents were obtained, including one on the stabilization of active lipids, the isolation of active fractions and the extraction process.
The greatest advance was the discovery of the competing fraction of pure Arachidonic Acid (AA), known as Lyprinol®. This led to the development of Lyprinol® Advanced, a synergistic combination of mussel and krill extracts that offers a new clinical option for treating inflammatory conditions.
When you visit any website, it may collect or store information on your browser, generally through the use of cookies. This information may be about you, your preferences, or your device, and is used primarily to make the site work as expected. The information generally does not directly identify you, but it can provide you with a more personalized web experience. Because we respect your right to privacy, you can choose not to allow us to use certain cookies. Click on each category heading to learn more and change our default settings. However, blocking some types of cookies may affect your experience on the site and the services we can offer.
[Cookies Policy] [More information]These cookies are necessary for the website to function and cannot be disabled in our systems. They are usually configured to respond to actions you take to receive services, such as adjusting your privacy preferences, logging into the site, or filling out forms. You can set your browser to block or alert the presence of these cookies, but some parts of the website will not work. These cookies do not store any personally identifiable information.
These cookies allow us to count visits and traffic sources so that we can measure and improve the performance of our site. They help us to know which pages are the most or least popular, and to see how many people visit the site. All the information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you visited our site, and therefore we will not be able to know when you visited it.
These cookies allow the site to offer better functionality and personalization. They may be set by us or by third parties whose services we have added to our pages. If you do not allow these cookies some of our services will not work properly. It also enables storage related to security, such as authentication functionality, fraud prevention, and other user protection.
These cookies may be throughout the website, placed by our advertising partners. These businesses may use them to build a profile of your interests and show you relevant ads on other sites. They do not store personal information directly, but are based on the unique identification of your browser and Internet access device. If you do not allow these cookies, you will have less targeted advertising.
These cookies are set by a number of social networking services that we have added to the site to allow you to share our content with your friends and networks. They are able to track your browser across other sites and create a profile of your interests. This may modify the content and messages you find on other web pages you visit. If you do not allow these cookies you will not be able to see or use these sharing tools.
